Please login to the form below

Not currently logged in
Email:
Password:

S-A collaborates to develop antibodies

S-A has entered into a global collaboration agreement to develop an antibody against an antigen present on the surface of carcinoma cells

Sanofi-aventis (S-A) has entered into a global collaboration agreement with Micromet to develop an antibody against an antigen present on the surface of carcinoma cells.

Under the terms of the agreement, Micromet will take responsibility for discovery, research and development of the antibody through the phase I clinical trial process, under the supervision of a Joint Steering Committee. Further development and worldwide commercialisation of the antibody will be sanofi-aventis' responsibility.

Upon signing the agreement, S-A will make an upfront payment of €8m to Micromet. Additionally, Micromet will be eligible for up to €312m in milestone and royalty payments.

"Micromet's BiTE antibodies represent a promising new approach to treating cancer," declared Marc Cluzel, senior vice-resident R&D, sanofi-aventis. "We believe BiTE antibodies have the potential to significantly expand the treatment options that we can offer to cancer patients in the future."

29th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics